| Title |
<i>Serenoa repens</i> for benign prostatic hyperplasia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2012
|
| DOI | 10.1002/14651858.cd001423.pub3 |
| Pubmed ID | |
| Authors |
James Tacklind, Roderick MacDonald, Indy Rutks, Judith U Stanke, Timothy J Wilt |
| Abstract |
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate, which can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (SR), which is also known by its botanical name of Sabal serrulatum, is one of several phytotherapeutic agents available for the treatment of BPH. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 26% |
| United States | 3 | 16% |
| Canada | 1 | 5% |
| Brazil | 1 | 5% |
| Unknown | 9 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 68% |
| Practitioners (doctors, other healthcare professionals) | 3 | 16% |
| Scientists | 3 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 350 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | <1% |
| Italy | 2 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| South Africa | 1 | <1% |
| Canada | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 341 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 57 | 16% |
| Student > Master | 53 | 15% |
| Researcher | 35 | 10% |
| Other | 28 | 8% |
| Student > Postgraduate | 25 | 7% |
| Other | 82 | 23% |
| Unknown | 70 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 150 | 43% |
| Nursing and Health Professions | 24 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 6% |
| Agricultural and Biological Sciences | 20 | 6% |
| Biochemistry, Genetics and Molecular Biology | 14 | 4% |
| Other | 43 | 12% |
| Unknown | 78 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 80. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2021.
All research outputs
#544,730
of 25,732,188 outputs
Outputs from Cochrane database of systematic reviews
#953
of 13,136 outputs
Outputs of similar age
#3,665
of 288,068 outputs
Outputs of similar age from Cochrane database of systematic reviews
#14
of 195 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,136 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,068 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 195 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.